Ultimate General Partner Se... Net Worth

Insiders trading at Guardant Health Inc

Over the last 6 years, insiders at Guardant Health Inc have traded over $2,653,630,540 worth of Guardant Health Inc stock and bought 2,438,210 units worth $45,173,576 . The most active insiders traders include Bluebird (Cayman) Ltd Softb..., Bluebird (Cayman) Ltd Svf E... y Helmy Eltoukhy. On average, Guardant Health Inc executives and independent directors trade stock every 6 days with the average trade being worth of $2,415,822. The most recent stock trade was executed by Kumud Kalia on 9 September 2024, trading 6,545 units of GH stock currently worth $162,774.

What does Guardant Health Inc do?

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Guardant Health Inc executives and stock owners

Guardant Health Inc executives and other stock owners filed with the SEC include:

• Michael Wiley,
  Chief Legal Officer
• Derek Bertocci,
  Chief Financial Officer
• Helmy Eltoukhy,
  Chief Executive Officer, Director
• AmirAli Talasaz,
  Chairman of the Board, President, Chief Operating Officer
• John G. Saia,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Michael J. Wiley,
  Head of Corp. Affairs
• Dr. Richard B. Lanman,
  Advisor
• Bahija Jallal,
  Independent Director
• Ian Clark,
  Lead Independent Director
• Stanley Meresman,
  Independent Director
• Samir Kaul,
  Independent Director
• Dr. AmirAli Talasaz Ph.D.,
  Co-CEO & Director
• Dr. Helmy Eltoukhy Ph.D.,
  Co-Founder, Co-CEO & Chairman
• Lynn Lewis,
  IR Contact Officer
• Vijaya Gadde,
  Director
• Kumud Kalia,
  Chief Information Officer
• Dr. Richard B. Lanman M.D.,
  Advisor
• Steven Collora,
  VP of Sales
• Daniel Simon,
  Sr. VP of Biopharma Bus. Devel.
• Andy Ament,
  Sr. VP of Operations
• Mark Jacobstein,
  Chief User Engagement Officer
• Amelia Merrill,
  VP of People
• Michael Bell,
  Chief Financial Officer
• Richard B. Lanman,
  Chief Medical Officer
• Terilyn J. Monroe,
  Chief People Officer
• Musa Tariq,
  Director
• Craig Eagle,
  Chief Medical Officer
• Meghan V. Joyce,
  Director
• Group Capital Ltd Softbank ...,
  
• Us (Ttgp), Ltd.Sc U.S. Vent...,
  
• Vision Fund (Aiv M1) L.P.Sb...,
  
• Beta Pte. Ltd.Temasek Life ...,
  
• Advisors Llc Orbimed,
  10% owner
• Ultimate General Partner Se...,
  
• Ventures Iv, L.P.Khosla Ven...,
  
• Ultimate General Partner X,...,
  
• Bluebird (Cayman) Ltd Softb...,
  
• Dipchand Nishar,
  Director
• Aaref Hilaly,
  Director
• John G. Saia,
  Chief Legal Officer
• Bluebird (Cayman) Ltd Svf E...,
  
• Chris Freeman,
  Chief Commercial Officer
• Myrtle S Potter,
  Director
• Steve E. Krognes,
  Director
• Michael Brian Bell,
  Chief Financial Officer
• Amelia Merrill,
  SVP, People
• Medina Manuel Hidalgo,
  Director
• Darya Chudova,
  Chief Technology Officer
• Ines Dahne Steuber,
  Chief Operating Officer